Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia

Atherosclerosis

Volumn 139, Issue 2, 1998, Pages 401-409

  Park, Jai Wun ^a   Merz, Mechthild ^a   Braun, Peter ^a  

^a Herzzentrum Duisburg   (Germany)

Author keywords

Coronary angiography; Coronary artery disease; Fibrinogen; LDL apheresis; Lipoprotein(a)

Indexed keywords

LIPOPROTEIN A; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; APHERESIS; ARTICLE; ATHEROGENESIS; BICYCLE ERGOMETRY; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SECONDARY PREVENTION; SURVIVAL; TREATMENT OUTCOME;

ADULT; BLOOD COMPONENT REMOVAL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; EXTRACORPOREAL CIRCULATION; FEMALE; FIBRINOGEN; HEPARIN; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PRECIPITATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0031877776     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00092-6     Document Type: Article

References (49)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. European Atherosclerosis Society International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-156.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993;269:3015-3020.
4. Thompson G.R., Lowenthal R., Myant N.B. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet. 1:1975;1208-1211.
5. Stoffel W., Borberg H., Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet. 2:1981;1005-1007.
6. Eisenhauer T., Armstrong V.W., Wieland H., Fuchs C., Scheler F., Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr. 65:1987;161168.
7. Homma Y., Mikami Y., Tamachi H., Nakaya N., Nakamura H., Goto Y. Comparison of selectivity of LDL removal by double filtration and dextransulfate cellulose column plasmapheresis and changes of subfractionated plasma lipoproteins after plasmapheresis in heterozygous familial hypercholesterolemia. Metabolism. 36:1987;419-423.
8. Badimon J.J., Fuster V., Chesebro J.H., Badimon L. Coronary atherosclerosis. A multifactorial disease. Circulation. 87(suppl 2):1993;3-16.
9. Fuster V., Stein B., Ambrose J.A., Badimon L., Badimon J.J., Chesebro J.H. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation. 82(suppl 2):1990;47-59.
10. The European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group, Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., van de Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med. 332:1995;635-641.
11. Cremer P., Nagel D., Labrot B., Mann H., Muche R., Elster H., Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 24:1994;444-453.
12. Kroon A.A., Aengevaeren W.R.M., van der Werf T., Uijen G.J.H., Reiber J.H.C., Bruschke A.V.G., Stalenhoef A.F.H. LDL-apheresis atherosclerosis regression study (LAARS). Circulation. 93:1996;1826-1835.
13. The HELP-Study Group, Schuff-Werner P., Gohlke H., Bartmann U., Baggio G., Corti M.C., Dinsenbacher A., Eisenhauer T., Grutzmacher P., Keller C., Kettner U., Kleophas W., Koster W., Olbricht C.J., Richter W.O., Seidel D. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentrations and the course of coronary heart disease. Eur J Clin Invest. 24:1994;724-732.
14. Tatami R., Inoue N., Itoh H., Kishino B., Koga N., Nakashima Y., Nishide T., Okamura K., Saito Y., Teramoto T., Yasugi T., Yamamoto A., Goto Y. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis. 95:1992;1-13.
15. AHA Committee A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc Committee for grading of coronary artery disease. Council on Cardiovascular Surgery, American Heart Association. Circulation. 51:1975;7-40.
16. The CCAIT Study Group, Waters D., Higginson L., Gladstone P., Kimball B., Le May M., Boccuzzi S.J., Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 89:1994;959-968.
17. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.-T., Kaplan C., Zhao X.-Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med. 323:1990;1289-1298.
18. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. J Am Med Assoc. 264:1990;3007-3012.
19. Watts G.F., Lewis B., Brunt J.N.H., Lewis E.S., Coltart D.J., Smith L.D.R., Mann J.I., Swan A.V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
20. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacLarlane P.W., McKillop J.H., Packard C.J. The West Of Scotland Coronary Prevention Study Group. New Engl J Med. 333:1995;1301-1307.
21. Benson H., McCallie D.P. Jr. Angina pectoris and the placebo effect. New Engl J Med. 300:1979;1424-1429.
22. Kleophas W., Leschke M., Tschoepe D., Martin J., Schauseil S., Schottenfeld Y., Strauer B.E., Gries F.A. Acute effects of extracorporeal elimination of low-density lipoprotein(LDL)-cholesterol and fibrinogen on blood rheology and microcirculation. Dtsch. med. Wschr. 115:1990;3-7.
23. The HELP Study Group, Seidel D., Armstrong V.W., Schuff-Werner P. The HELP-LDL-apheresis multicentre study: an angiographycally assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest. 21:1991;375-383.
24. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (first of two parts). New Engl J Med. 326:1992;242-250.
25. Davies M.J., Thomas A.C. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 53:1985;363-373.
26. Brown B.G., Zhao X.-Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
27. Farb A., Burke A.P., Tang A.L., Liang Y., Mannan P., Smialek J., Virmani R. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1996;1354-1363.
28. Terres W., Tatsis E., Pfalzer B., Beil U., Beisiegel U., Hamm C.W. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation. 91:1995;948-950.
29. Yarnell J.W.G., Baker I.A., Sweetnam P.M., Bainton D., O'Brien J.R., Whitehead P.J., Elwood P.C. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 83:1991;836-844.
30. Kannel W.B., Wolf P.A., Castelli W.P., D'Agostino R.B. Fibrinogen and risk of cardiovascular disease: the Framingham Study. J Am Med Assoc. 258:1987;1183-1186.
31. Cooper J., Douglas A.S. Fibrinogen level as a predictor of mortality in survivors of myocardial infarction. Fibrinolysis. 5:1991;105-108.
32. Handa K., Kono S., Saku K., Sasaki J., Kawano T., Sasaki Y., Hiroki T., Arakawa K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis. 77:1989;209-213.
33. Marcovina S.M., Morrisett J.D. Structure and metabolism of lipoprotein (a). Curr Opin Lipidol. 6:1995;136-145.
34. Labeur C., De Bacquer D., De Backer G., Vincke J., Muyldermans L., Vandekerckhove Y., Van der Stichele E., Rosseneu M. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem. 38:1992;2261-2266.
35. Seed M., Hoppichler F., Reaveley D. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. New Engl J Med. 322:1990;1494-1499.
36. Rhoads G., Dahlen G., Berg K., Morton N., Dannenberg A.L. Lp(a) lipoprotein as a risk factor for myocardial infarction. J Am Med Assoc. 256:1986;2540-2544.
37. Schaefer E.L., Lamon-Fava S., Lenner J.L., McNamara J., Ordovas J., Davis E., Abolafia J.M., Lippel K., Levy R.I. Lipoprotein(a) levels and risk of coronary heart disease in men. J Am Med Assoc. 271:1994;999-1003.
38. McLean J.W., Tomlinson J.E., Kuan W.-J., Eaton D.L., Chen K.Y., Fless G.M., Scanu A.M., Lawn R.M. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 330:1987;132-137.
39. Loscalzo J., Weinfeld M., Fless G.M., Scanu A.M. Lipoprotein (a), fibrin binding and plasminogen activation. Arteriosclerosis. 10:1990;240-245.
40. Hajjar K.A., Gavish D., Breslow J.L., Nachman R.L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
41. Ezratty A., Simon D.I., Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry. 32:1993;46284633.
42. Knisel W., Di Nicuolo A., Pfohl M., Müller H., Risler T., Eggstein M., Seifried E. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic system. J Intern Med. 234:1993;479-487.
43. Schuff-Werner P. Untersuchungen zur hämorheologischen Wirksamkeit der LDL-Apherese. Habilitationsschrift. Melsungen: Bibliomed Med, 1993:54-57.
44. Maher V.M.G., Brown B.G. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 6:1995;229-235.
45. Thompson G.R., Maher V.M.G., Matthews S., Kitano Y., Nenwirth C., Shortt M.B., Davies G., Rees A., Mir A., Prescott R.J., de Feyter P., Henderson A. Familial Hypercholesterolemia Regression Study: a randomized trial of low-density lipoprotein apheresis. Lancet. 345:1995;811-816.
46. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 995;345:1274-1275.
47. Thompson G.R., Holler J., Waters D.D. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 6:1995;386-388.
48. Park J.-W., Vermeltfoort M., Braun P., May E., Merz M. Regression of transplant coronary artery disease during chronic HELP therapy: A case study. Atherosclerosis. 115:1995;1-8.
49. Park J.-W., Merz M., Braun P. Regression of transplant coronary artery disease during chronic LDL-apheresis. J Heart Lung Transplant. 16:1997;290-297.